Evolution of the Average Target: enGene Therapeutics Inc.

Evolution of the Average Target - enGene Therapeutics Inc.

Evolution of the Target Price: enGene Therapeutics Inc.

Evolution of the Target Price - enGene Therapeutics Inc.

Changes in Analyst Recommendations: enGene Therapeutics Inc.

8dc0542fcf28f1deee0f1640.F-sRHKTzyH0KQJGZx491c2k4n-fTHZuJJ0k6skeI410.RaZGSMCypzk5LNPNpMNAKg9_zKKCTNDmUD8Cyj7FrDd9o3Ze0ZXxTXsK0A~241ab7720fae8eaff90d004745c9a93b
11-13 Leerink Partners Upgrades enGene to Outperform From Market Perform, $5 Price Target MT
11-12 Wells Fargo Upgrades enGene Holdings to Overweight, Price Target is $6 MT
06-18 EnGene Shares Fall After Morgan Stanley Downgrade MT
06-18 EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says MT
06-18 Morgan Stanley Downgrades enGene to Underweight From Equalweight MT
01-30 Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target MT
11-12 Oppenheimer Adjusts Price Target on enGene Holdings to $33 From $30, Maintains Outperform Rating MT
11-12 UBS Boosts Price Target on enGene Holdings to $10 From $4, Keeps Neutral Rating MT
11-11 Raymond James Upgrades enGene Holdings to Strong Buy From Outperform, Adjusts PT to $27 From $23 MT
11-11 EnGene's Mid-Stage Trial Shows Improved Complete Response Rate in Non-Muscle Invasive Bladder Cancer Patients MT
18/02/25 Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target MT
14/02/25 EnGene Holdings Shares Fall After UBS Downgrade MT
14/02/25 UBS Downgrades enGene Holdings to Neutral From Buy, Cuts Price Target to $7 From $34 MT
23/12/24 HC Wainwright Initiates Coverage on enGene Holdings With Buy Rating, $25 Price Target MT
27/11/24 Raymond James Initiates enGene at Outperform With $23 Price Target MT
18/11/24 JMP Securities Initiates enGene Holdings at Market Outperform With $18 Price Target MT
28/08/24 Oppenheimer Initiates Coverage on enGene Holdings With Outperform Rating, $30 Price Target MT
22/04/24 Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target MT
15/04/24 Guggenheim Starts enGene Holdings With Buy Rating, $34 Price Target MT
28/03/24 UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target MT
08/03/24 Morgan Stanley Starts Coverage on Engene With Overweight Rating, $40 Price Target MT
20/02/24 Leerink Partners Starts enGene Holdings With Outperform Rating, $31 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+149.17%
+38.52%
+18.89%
+8.54%
+13.54%
+21.07%
+30.77%
+68.83%
+19.8%
+59.35%
Average +42.85%
Weighted average by Cap. +28.58%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.720USD
Average target price
4.286USD
Spread / Average Target
+149.17%
High Price Target
6.000USD
Spread / Highest target
+248.84%
Low Price Target
2.000USD
Spread / Lowest Target
+16.28%

Analyst Consensus Detail

Analyst consensus - enGene Therapeutics Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - enGene Therapeutics Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - enGene Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ENGN Stock
  4. Consensus enGene Therapeutics Inc.